Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Ranging Study Assessing the Safety, Tolerability, Immunogenicity of Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV-2 Spike and Nucleocapsid Proteins (ORFEUS Study)

NCT05367843 is registered in ClinicalTrials.gov with Speransa Therapeutics as lead sponsor.

NCT NCT05367843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05367843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Ranging Study Assessing the Safety, Tolerability, Immunogenicity of Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV-2 Spike and Nucleocapsid Proteins (ORFEUS Study)
Lead sponsor
Speransa Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
June 20, 2022
Completion date
November 8, 2023
Enrollment
103 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection